Erivedge [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2015.
4 Medicines.co.uk. Erivedge 150 mg hard capsules: Summary of product characteristics. Available at https://http://www.medicines.org.uk/emc/medicine/28107. Accessed April 4, 2016.
Migden, MR, Guminski, A, Gutzmer, R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015; 16: 716-728 [OpenAIRE] [PubMed]
Sekulic, A, Migden, MR, Lewis, K. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015; 72: 1021-6.e8 [PubMed]
Sekulic, A, Migden, MR, Basset-Seguin, N. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study. J Clin Oncol. 2014; 32 (suppl): 9013a [OpenAIRE]
Chang, ALS, Solomon, JA, Hainsworth, JD. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014; 70: 60-69 [PubMed]
Lacouture M, Guillen J, Kudchadkar R et al. Management of frequent vismodegib-related adverse events in patients with locally advanced basal cell carcinoma: RegiSONIC Disease Registry Study. Poster presented at the 74th Annual Meeting of the American Academy of Dermatology; March 6, 2016; Washington, DC.
Sofen, H, Gross, KG, Goldberg, LH. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015; 73: 99-105.e1 [PubMed]
Basset-Seguin, N, Hauschild, A, Grob, J-J. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): A pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015; 16: 729-736 [OpenAIRE] [PubMed]